Latest Biotech News

Odyssey Therapeutics priced an upsized IPO and concurrent private placement to raise $304 million as it advances its lead Phase II program for ulcerative colitis and plans further development...

Regulatory timelines shifted for Alzheimer’s therapy lecanemab (Leqembi) as the FDA delayed a decision on the company’s proposed subcutaneous route. Biogen and Eisai said the decision date was...

Guardant Health beat expectations with a Q1 2026 revenue surge, raised full-year guidance, and pointed to continued momentum in oncology and screening. The company reported Q1 revenue of $301.7...

Mobia Medical began trading on Nasdaq after pricing its IPO at $15 per share, raising about $150 million. The company sold 10 million shares at the midpoint of its $14–$16 target range and ended...

10x Genomics forecast dimmed spatial biology sales as it rolls out its Atera in situ spatial platform and reiterated full-year guidance. In a business update tied to the platform launch, the...

10x Genomics sued Element Biosciences over alleged patent infringement involving Element’s Aviti24 multiomic analysis platform. The complaint, filed in the District of Delaware, alleges Aviti24...

Arrivent Biopharma received FDA IND clearance for ARR-002 (AV-P138-ADC), an antibody-drug conjugate targeting MUC16 and NaPi2b. The IND clearance enables initiation of a Phase I trial expected to...

Amplified Sciences initiated patient enrollment for PanAMP, a multicenter clinical utility study designed to evaluate how its PanCystPro assay influences clinical decision-making for early...

Regeneron won FDA accelerated approval for Otarmeni (lunsotogene parvec-cwha), positioned as the first in vivo gene therapy to restore neurosensory hearing for children and adults with...

Natera raised its 2026 revenue guidance after Q1 results showed a sharp acceleration across oncology and women’s health testing. The company increased full-year guidance to $2.74 billion to $2.82...

Bayer moved to expand its ophthalmology portfolio by acquiring Perfuse Therapeutics for $2.45 billion, gaining full rights to PER-001, a Phase II endothelin receptor antagonist for glaucoma and...

Researchers reported promising Phase II data for cancer of unknown primary (CUP) using a second-line regimen combining an anti–PD-1 immune checkpoint inhibitor with nab-paclitaxel. The study, led...

10x Genomics launched Atera, a new in situ spatial biology platform aimed at whole-transcriptome mapping with single-cell sensitivity at scale. The company said Atera is engineered to work across...

Caris Life Sciences submitted an application to the New York State Department of Health’s Clinical Laboratory Evaluation Program for authorization to perform Caris Assure in-state. The review will...

Odyssey Therapeutics completed an upsized IPO and concurrent private placement, raising $304 million to fund clinical-stage autoimmune and inflammatory pipeline development. The company priced...

Arrivent Biopharma received FDA IND clearance for ARR-002 (AV-P138-ADC), marking a step toward initiating a Phase I trial focused first on ovarian and endometrial cancers and expanding across...

ParcelBio raised $13 million in seed financing to build its APEXm platform for durable protein expression and to advance an in vivo CAR T program for autoimmune disease. The round was led by...

Pacific Biosciences trimmed the high end of its 2026 revenue guidance after lower-than-anticipated instrument demand and continued softness in academic funding, particularly in the Americas. The...

The FDA granted accelerated approval to Regeneron’s Otarmeni (lunsotogene parvec-cwha), positioning it as the first gene therapy designed to restore neurosensory function for OTOF-related...

Reports say Moderna has begun early-stage research into a hantavirus vaccine, a development that immediately moved investor expectations and reignited interest in unmet infectious-disease...